Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Shionogi Yönetim

Yönetim kriter kontrolleri 4/4

Shionogi's CEO'su Isao Teshirogi, Apr2008 tarihinde atandı, in görev süresi 16.5 yıldır. in toplam yıllık tazminatı ¥ 272.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 35.3% maaş ve 64.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.028% ine doğrudan sahiptir ve bu hisseler € 3.16M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.5 yıl ve 5.3 yıldır.

Anahtar bilgiler

Isao Teshirogi

İcra Kurulu Başkanı

JP¥272.0m

Toplam tazminat

CEO maaş yüzdesi	35.3%
CEO görev süresi	16.5yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	6.5yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Isao Teshirogi'un ücretlendirmesi Shionogi'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	JP¥150b
Mar 31 2024	JP¥272m	JP¥96m	JP¥162b
Dec 31 2023	n/a	n/a	JP¥154b
Sep 30 2023	n/a	n/a	JP¥218b
Jun 30 2023	n/a	n/a	JP¥193b
Mar 31 2023	JP¥291m	JP¥93m	JP¥185b
Dec 31 2022	n/a	n/a	JP¥201b
Sep 30 2022	n/a	n/a	JP¥118b
Jun 30 2022	n/a	n/a	JP¥117b
Mar 31 2022	JP¥244m	JP¥84m	JP¥114b
Dec 31 2021	n/a	n/a	JP¥97b
Sep 30 2021	n/a	n/a	JP¥116b
Jun 30 2021	n/a	n/a	JP¥123b
Mar 31 2021	JP¥241m	JP¥84m	JP¥112b
Dec 31 2020	n/a	n/a	JP¥117b
Sep 30 2020	n/a	n/a	JP¥120b
Jun 30 2020	n/a	n/a	JP¥119b
Mar 31 2020	JP¥160m	JP¥84m	JP¥122b
Dec 31 2019	n/a	n/a	JP¥129b
Sep 30 2019	n/a	n/a	JP¥126b
Jun 30 2019	n/a	n/a	JP¥125b
Mar 31 2019	JP¥198m	JP¥84m	JP¥133b
Dec 31 2018	n/a	n/a	JP¥123b
Sep 30 2018	n/a	n/a	JP¥116b
Jun 30 2018	n/a	n/a	JP¥125b
Mar 31 2018	JP¥160m	JP¥84m	JP¥109b

Tazminat ve Piyasa: Isao 'nin toplam tazminatı ($USD 1.89M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.31M ).

Tazminat ve Kazançlar: Isao 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Isao Teshirogi (65 yo)

16.5yrs

Görev süresi

JP¥272,000,000

Tazminat

Dr. Isao Teshirogi, Ph D., serves as Chairman at Shionogi & Co., Ltd. since July 01, 2022.He is Independent Outside Director at Japan Exchange Group, Inc. since June 19, 2024. Dr. Teshirogi serves as Inde...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Isao Teshirogi	CEO, President & Chairman	16.5yrs	JP¥272.00m	0.028% ¥ 3.1m
Susumu Mitsumori	Vice President of Finance & Accounting Department	2.3yrs	Veri yok	Veri yok
Ryuichi Kiyama	Senior Executive Officer & Senior VP of Administration Division	less than a year	Veri yok	Veri yok
Takeshi Shiota	Corporate Officer and Senior VP of Corporate Quality Assurance	2.8yrs	Veri yok	Veri yok
Yoshimasa Kyokawa	Vice President of Corporate Communications & Secretary Office	6.5yrs	Veri yok	Veri yok
Yoshihiro Furuya	Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office	8.5yrs	Veri yok	Veri yok
Kohji Hanasaki	Senior Executive Officer and Senior VP of Supply Supervisory Unit	7.5yrs	Veri yok	Veri yok
John A. Keller	Senior Executive Officer and Senior VP of R&D Supervisory Unit	7.5yrs	Veri yok	Veri yok
Kazuhiro Hatanaka	Senior Executive Officer & Senior VP of Corporate Strategy Division	no data	Veri yok	Veri yok
Akira Kato	Senior Executive Officer & President of Shionogi Pharma Co.	no data	Veri yok	Veri yok
Toshinobu Iwasaki	Senior Executive Officer & Senior VP of Healthcare Business Supervisory Unit	no data	Veri yok	Veri yok
Masashi Deguchi	Corporate Officer & Senior VP of DX Promotion Division	2.8yrs	Veri yok	Veri yok

6.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: SH00 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Isao Teshirogi	CEO, President & Chairman	22.3yrs	JP¥272.00m	0.028% ¥ 3.1m
Hiroshi Ozaki	Independent Outside Director	5.3yrs	Veri yok	Veri yok
Tsuguoki Fujinuma	Independent Outside Corporate Auditor	5.3yrs	Veri yok	0.00035% ¥ 38.2k
Takuko Yamada-Sawada	Vice Chairman of the Board	9.3yrs	JP¥157.00m	0.018% ¥ 2.0m
Shuichi Okuhara	Outside Corporate Auditor	4.3yrs	Veri yok	Veri yok
Takaoki Fujiwara	Independent Outside Director	1.3yrs	Veri yok	Veri yok
Keiichi Ando	Independent Chairperson of the Board	8.3yrs	Veri yok	Veri yok
Akira Okamoto	Standing Corporate Auditor	9.3yrs	Veri yok	0.0021% ¥ 231.1k
Noriyuki Kishida	Full-time Auditor	less than a year	Veri yok	0.0021% ¥ 231.1k
Fumi Takatsuki	Independent Outside Director	4.3yrs	Veri yok	Veri yok
Yoriko Goto	Outside Corporate Auditor	1.3yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SH00 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Shionogi Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shionogi & Co., Ltd., Annual General Meeting, Jun 20, 2024

Shionogi & Co., Ltd., Annual General Meeting, Jun 21, 2023

Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment

Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment

Recent updates

Shionogi & Co., Ltd. Submits New Drug Application in Japan for Zuranolone as A Treatment for Major Depressive Disorder

Shionogi & Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025

Shionogi & Co., Ltd. to Report Q2, 2025 Results on Oct 28, 2024

Shionogi & Co., Ltd. to Report Q1, 2025 Results on Jul 29, 2024

Shionogi & Co., Ltd., Annual General Meeting, Jun 20, 2024

Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study (PERSEUS) of Fetroja®/F etcroja® (cefiderocol)

Shionogi & Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024

Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan

Shionogi & Co., Ltd. Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open

Shionogi & Co., Ltd Announces the Launch of Fetroja(Cefiderocol) Intravenous Infusion 1g Vial in Japan on December 20, 2023

Shionogi & Co., Ltd. Initiation of a Phase 3 Additional Dose Clinical Trial in Japanese Subjects of the Monovalent Vaccine for the XBB1.5 Strain, S-268023

Shionogi & Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Shionogi & Co., Ltd. Presents New Real-World Evidence Demonstrating Effectiveness of Early Treatment with Fetroja®? (Cefiderocol) in Appropriate Patients

Shionogi & Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Shionogi & Co., Ltd. (TSE:4507) announces an Equity Buyback for 12,500,000 shares, representing 4.2% for ¥7,500 million.

Eddingpharm Announces Approval of Mulpleta®? (Lusutrombopag) in China

Shionogi & Co., Ltd. Announces Initiation of a Phase 3 Clinical Trial in Japanese Pediatric Patients of Ensitrelvir for COVID-19

Shionogi & Co., Ltd. Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Shionogi & Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Shionogi & Co., Ltd. Announces Year-End Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023; Provides Dividend Guidance for the End of Second Quarter of Fiscal Year 2024

Shionogi & Co., Ltd., Annual General Meeting, Jun 21, 2023

Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Announces Availability of Innovative Antibiotic, Cefiderocol in Norway

Shionogi & Co., Ltd. Announces Initiation of Phase1/2/3 Clinical Trial (Part 2), Phase 3 Additional Dose Clinical Trial in Japanese Pediatric of the COVID-19 Vaccine, S-268019

Shionogi & Co., Ltd. to Report Q3, 2023 Results on Jan 30, 2023

Shionogi & Co., Ltd. Files for Approval of S-268019, A COVID-19 Recombinant Protein-Based Vaccine, in Japan

Shionogi & Co., Ltd. Announces Tablets 125Mg Approved in Japan for the Treatment of SARS-CoV-2 Infection

Shionogi & Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2022, Payable on December 1, 2022

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for First Half of the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Announces Achievement of the Primary Endpoint for Ensitrelvir (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia

Shionogi & Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

Shionogi & Co., Ltd Announces Ensitrelvir Fumaric Acid (S-217622), Therapeutic Drug for COVID-19,Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75

Shionogi & Co., Ltd. Provides Year-End Dividend Guidance for the Year Ending March 31, 2023

Shionogi & Co., Ltd. Initiates Fourth Vaccination Trail

Shionogi & Co., Ltd. Announces Initiation of A Clinical Trial in Japanese Pediatric Subjects of the COVID-19 Recombinant Protein-Based Vaccine, S-268019

Shionogi & Co., Ltd. Announces S-217622, A Therapeutic Drug for Covid-19, Shows High in Vitro Antiviral Activity Against Omicron Subvariants BA.4 and BA.5

Shionogi & Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment

Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment

Shionogi & Co. Announces Initiation of a Phase 2/3 Clinical Trial in Japanese Adolescents for the Covid-19 Recombinant Protein-Based Vaccine, S-268019

Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2022 and Full Year Ending March 31, 2023

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş